What EMS does

EMS is the largest pharmaceutical company in Brazil and market leader for 20 consecutive years, accounting for approximately 14% of all medicines sold in the country by volume. Founded in 1964 and controlled by the Sanchez family through Grupo NC (rebranded as Grupo EMS in June 2026), the company operates across four core business units: prescription medications (innovative branded Rx), generics (~400 SKUs generating over R$3.4 billion annually and ~15.8% value share, expanding to 31% post-Medley acquisition), OTC consumer health (Dermacyd, Lacday, MultiMix, Neosil, Gerovital), and Hospitalar (injectables, recently strengthened via Fresenius Kabi Brasil acquisition). The company employs approximately 7,300 direct collaborators (12,000 across the group) and operates six Brazilian manufacturing plants producing over 1 billion units annually, with distribution extending to 60+ countries via subsidiaries in the US (Vero Biotech, Brace Pharma), Serbia (Galenika), Italy (Monteresearch), and Mexico (KSK).

EMS's core technology is a full-stack pharmaceutical manufacturing capability spanning conventional generics, branded Rx, OTC products, and — most distinctively — solid-phase chemical synthesis of GLP-1 peptide analogues at Brazil's only domestic peptide manufacturing facility in Hortolândia, São Paulo, inaugurated in 2024 with R$1.2B+ in invested capital and capacity of up to 40 million pens per year. The company's GLP-1 platform includes LIRUX (liraglutida, August 2025), OLIRE (liraglutida, March 2026), and OZIVY (semaglutida, May 2026), all classified by ANVISA as 'novo medicamento' rather than generics, distinguishing EMS from follow-on competitors. EMS also co-develops RNA-based therapies with US biotech miRecule via the NAVIgGator platform through Rio Biopharmaceuticals.

EMS generates revenue through five streams: prescription (innovator brand sales via medical representatives/propagandistas), generics (regulated by CMED at minimum 35% below reference brand pricing), OTC (retail pharmacy distribution), Hospitalar (hospital procurement), and the EMS Saúde subscription-based discount program (CPF-enrolled patient loyalty). The go-to-market combines prescription drug detailing to physicians across Brazil, broad pharmacy retail distribution for generics and OTC, hospital direct sales, and direct-to-consumer digital programs (Vida + Leve, LacLovers, Durma Bem, +Ofta). Major partnerships include Idorsia (QUVIVIQ for insomnia, LatAm), BNDES (R$500M innovation financing), WHO (yaws eradication drug donation), and Africa Creative (institutional advertising). Revenue trajectory is supported by ongoing M&A (Medley, Fresenius Kabi), international expansion, and entry into the GLP-1 therapeutics market.

Name

EMS

Legal name

EMS S/A

Website

https://ems.com.br

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

11–50 employees

Short description

EMS is Brazil's largest pharmaceutical company, controlling roughly 14% of the domestic drug market through generics, branded Rx, OTC, and hospital segments, and operating the country's only domestic peptide manufacturing facility for GLP-1 therapies. The Sanchez-family-owned conglomerate serves patients, physicians, and hospitals across 60+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)

Keywords

• Generic pharmaceuticals
• Prescription medications
• GLP-1 peptide therapies
• Over-the-counter consumer health
• Hospital injectable medicines

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices11 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Prescription (Inovadores / Marca): Revenue from branded innovative prescription medicines sold through medical detailing to prescribing physicians across all therapeutic areas.
2. Generic Medicines (Genéricos): Revenue from generic pharmaceutical products. EMS leads Brazil's generic segment since 2013, with approximately 400 product presentations, generating over R$3.4 billion/year in revenue. Generics represent about 40% of Brazil's pharmaceutical market.
3. OTC (Over-the-Counter / Consumer Health): Revenue from OTC products including Dermacyd (intimate care), Lacday (lactase enzyme), and MultiMix (functional lozenges), sold through pharmacy retail chains. EMS Saúde discount program drives consumer loyalty and repeat purchases.
4. Hospitalar (Hospital): Revenue from supplying medications and solutions to hospitals and healthcare institutions. EMS recently acquired Fresenius Kabi's injectable portfolio and Anápolis manufacturing plant to strengthen this segment.
5. EMS Saúde Discount Program: Patient loyalty and discount program offering reduced prices on EMS medications in exchange for enrollment (CPF-based), generating recurring prescription purchases and patient data.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

Core offering

EMS is Brazil's largest pharmaceutical manufacturer, producing and distributing a diversified portfolio of generic medicines (~400 SKUs), branded prescription drugs, over-the-counter consumer health products (Dermacyd, Lacday, MultiMix, Neosil), and hospital injectable medications. The company operates six Brazilian manufacturing plants producing more than 1 billion units per year and runs Brazil's only domestic peptide manufacturing facility in Hortolândia, producing GLP-1 analog pens (Ozivy, Olire, Lirux) for diabetes and obesity treatment. Its products reach consumers through approximately 26.4 million boxes of generics dispensed monthly across Brazilian pharmacy retail chains.

Product overview

EMS is Brazil's largest pharmaceutical company and market leader for 20 consecutive years, offering a diversified portfolio across prescription medications, generic drugs, OTC products, and hospital medications. The company operates through multiple business units including the recently rebranded Grupo EMS, which consolidates brands like EMS, Germed, Legrand, Nova Química, Brace Pharma, Multilab, Ofta, and Under Skin. EMS's product portfolio centers on GLP-1 therapies (OZIVY, OLIRE, LIRUX) for diabetes and obesity manufactured at Brazil's first peptide factory, supported by generic medications (~400 presentations generating R$3.4 billion annually), and OTC products including Dermacyd intimate care, Lacday lactose enzyme, MultiMix functional lozenges, and Neosil beauty line. The company has expanded internationally through subsidiaries (Vero Biotech, Brace Pharma in USA; Galenika in Serbia; Monteresearch in Italy) and strategic partnerships (Idorsia for QUVIVIQ, miRecule for RNA therapeutics). Recent acquisitions include Medley generics brand from Sanofi and Fresenius Kabi Brasil's injectable portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• EMS Saúde: Patient benefit and discount program for EMS medications
• LacLovers
• Vida Mais Leve
• Durma Bem
• +Ofta
• Lacday Long Action
• Dermacyd
• Ozivy
• Olire
• Lirux
• Neosil
• Gerovital
• MultiMix

Products and services

• Ozivy Semaglutide-based GLP-1 pen injector for type 2 diabetes treatment, produced via chemical synthesis at EMS's peptide factory in Hortolândia. Classified as a 'novo medicamento' (new drug) by ANVISA with manufacturing capacity for up to 40 million pens annually. Targeted at patients requiring innovative GLP-1 therapy for diabetes management.
• Olire Liraglutide-based GLP-1 pen for obesity and type 2 diabetes treatment, the first Brazilian-manufactured GLP-1 analog via chemical synthesis. ANVISA approved as new medication. Targeted at physicians and specialists treating patients with diabetes and obesity.
• Lirux Liraglutide pen for type 2 diabetes and obesity treatment, produced via chemical synthesis at EMS's peptide manufacturing facility. Represents EMS's experience in peptide-based therapeutics. Targeted at physicians prescribing GLP-1 therapy for chronic disease management.
• EMS Generic Medications Portfolio Portfolio of approximately 400 generic medication presentations covering virtually all medical specialties. EMS has led Brazil's generic segment since 2013 with 15.8% market share by value, generating over R$3.4 billion annually with 26.4 million units sold monthly. Sold through pharmacy retail chains across Brazil at mandated minimum 35% below reference brand pricing.
• EMS Branded Prescription Medications Innovative prescription medications targeting physicians and healthcare professionals for specific treatment needs across all medical specialties. Sold through medical detailing to physicians and dispensed at pharmacies. Includes branded specialty therapies across cardiovascular, diabetes, oncology, immunology, and virology.
• Lacday Long Action First and only extended-release lactose enzyme supplement in Brazil, providing up to 8 hours of action with a single tablet. Represents innovation in the lactose intolerance treatment category, sold OTC at pharmacies nationwide and supported by the LacLovers patient program.
• Dermacyd Intimate care product line including Dermacyd Neutralize with exclusive Odor Control technology. Brand leader and pioneer in feminine intimate soaps in Brazil since the 1980s, acquired by EMS from Sanofi in 2023 for €66 million. Sold OTC through pharmacy retail chains targeting women consumers.
• MultiMix Functional lozenges line based on herbs, vitamin C, and zero sugar. Launched September 2025, positioned in the OTC segment with innovation focus. Sold through pharmacy retail chains targeting consumer health buyers.
• Neosil Line dedicated to hair health, nails, and skin care. Announced as part of EMS's wellness portfolio expansion, supported by Africa Creative agency marketing. Sold through pharmacy retail chains as OTC beauty and wellness products.
• EMS Hospital Injectables Portfolio Medications and solutions supplied to hospitals ensuring efficiency and safety in treatments, including the recently acquired injectable portfolio from Fresenius Kabi Brasil via Newcom Farmacêutica. Serves hospital procurement channels across Brazil.
• Vida Mais Leve Patient Program Patient benefit program for GLP-1 liraglutide medications for obesity and type 2 diabetes, offering therapeutic journey support, informational resources, telemedicine access via ConectaMédico, special pricing conditions, and BD Embecta injection needles. Targeted at patients using GLP-1 canetas (Ozivy, Olire, Lirux).
• EMS Saúde Discount Program Subscription loyalty and discount program offering reduced prices on EMS medications at participating pharmacies. Patients enroll via CPF (Brazilian tax ID) through phone (0800 9418 585) or website (emssaude.com.br) to access benefits. Drives recurring prescription purchases and patient data.
• EMS Patient Engagement Programs (LacLovers, Durma Bem, +Ofta) Loyalty and engagement programs including LacLovers for lactose intolerance, Durma Bem for sleep support, and +Ofta for eye care, collecting patient data for personalized healthcare interactions and driving repeat purchases of related EMS products.
• Quviviq Distribution (Latin America) Distribution partnership with Idorsia Pharmaceuticals to bring insomnia drug QUVIVIQ to Latin America, with EMS responsible for registration, commercialization, and milestone payments. Brings innovative insomnia therapeutic to Brazilian and Latin American markets.

Quantifiable outcome

• EMS holds 31% combined generics market share in Brazil post-Medley acquisition (EMS 23% + Medley 8%)
• +5 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• miRecule (USA)coreStrategic or Co-development Partner · 16 April 2026EMS established a partnership with US biotech miRecule for the co-development of RNA-based therapies targeting rare neuromuscular diseases using miRecule's proprietary NAVIgGator™ platform. The collaboration involves EMS/Rio Biopharmaceuticals in oligonucleotide production, therapeutic development, and early-phase clinical trials in Brazil. This is structured as a co-development agreement, not just investment.
• Sanofi (Medley Acquisition)coreStrategic or Co-development Partner · 6 March 2026EMS Group signed a definitive agreement to acquire 100% of Medley, one of Brazil's leading generic drug brands, from Sanofi for approximately R$3.2 billion (~$670 million, ~16x EBITDA). The transaction requires CADE approval. The deal combines Medley's brand strength in Brazil's generics market with EMS's industrial scale and manufacturing capabilities, consolidating EMS as Brazil's generics leader with 31% combined market share.
• Idorsia PharmaceuticalscoreGTM or Marketing Partner · 28 January 2026EMS S.A. entered a partnership with Idorsia Pharmaceuticals to bring the insomnia drug QUVIVIQ to Latin America, following regulatory submission in Brazil. EMS is responsible for registration, commercialization, and milestone payments. QUVIVIQ is already marketed in several countries and offers a therapeutic alternative for insomnia treatment.
• WHO (World Health Organization)minorStrategic or Co-development PartnerEMS signed a partnership agreement with the World Health Organization to donate oral azithromycin to support the eradication of yaws (bouba) globally. EMS is the first private company to donate medications for this WHO initiative, aligning with its mission to promote health access worldwide.
• PróGenéricos (Brazilian Generic Medicines Association)minorStrategic or Co-development PartnerEMS participates in industry advocacy through PróGenéricos (Brazilian Association of Generic Medicines and Biosimilars), which publishes market data on the Brazilian generics sector including economic impact and growth projections used by EMS in its market communications.
• Fresenius Kabi BrasilcoreStrategic or Co-development PartnerEMS completed the acquisition of an injectable medicines portfolio and corresponding manufacturing plant in Anápolis (GO) from Fresenius Kabi Brasil. The transaction was conducted via newly formed vehicle Newcom Farmacêutica Ltda. and involves full regulatory transfer of product registrations per RDC 903/2024. This strengthens EMS's Hospitalar (hospital) business segment.
• Africa Creative (Advertising Agency)coreGTM or Marketing PartnerAfrica Creative became EMS's institutional advertising agency, responsible for brand positioning, institutional communications, Ozivy (semaglutida caneta) launch communication, and Neosil (hair, nail, skin) product marketing. Africa Creative is ranked #1 in Brazil's Cenp-Meios media buying ranking and is the only Latin American agency in the Warc Creative 100 Top 10.
• BD Embecta (Injection Needles)minorChannel Partner/ Reseller/ DistributorEMS's Vida + Leve patient program includes a partnership with BD Embecta for the provision of injection needles at special conditions for patients using GLP-1 canetas (Ozivy, Olire, Lirux) for diabetes and obesity treatment.
• ConectaMédico (Telemedicine)minorChannel Partner/ Reseller/ DistributorEMS's Vida + Leve patient support program includes access to telemedicine services via ConectaMédico, enabling remote physician consultations for patients in treatment with GLP-1 canetas, supporting treatment adherence and clinical follow-up.
• Consórcio Cristo Sustentável (Sustainability Consortium)minorStrategic or Co-development PartnerEMS partnered with the Consórcio Cristo Sustentável (an alliance between Santuário Arquidiocesano Cristo Redentor, Obra Social Leste Um – O Sol, and Instituto RedentOR) to donate OTC medicines to social projects, aligning with EMS's social responsibility initiatives.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hypera Pharma: Brazil's second-largest pharmaceutical company and direct competitor across generics, OTC, and prescription segments. Hypera was the target of EMS's failed October 2024 merger bid, making them the most directly comparable peer in the Brazilian pharma landscape.
• Eurofarma Laboratórios: Privately-held Brazilian pharmaceutical company competing directly with EMS across generics, branded prescriptions, and hospital injectables. Like EMS, Eurofarma invests heavily in R&D and operates international subsidiaries across Latin America.
• Aché Laboratórios Farmacêuticos: Brazilian pharmaceutical manufacturer competing across prescription, OTC, and generics segments. Aché was among the bidders for Medley in 2026, positioning it as a direct competitive threat to EMS in the consolidated generics market.
• Biolab Farmacêutica: Brazilian pharmaceutical company with presence in prescription, generics, and hospital segments. Biolab was also a competing bidder for Medley in 2026, making it a relevant peer for assessing generics M&A dynamics and product overlap.
• Medley (Sanofi): Brazilian generics brand acquired by EMS from Sanofi for R$3.2-3.6B in 2026. Although now part of EMS, Medley's brand strength and ~8% market share make it a peer reference point for the combined entity's generics portfolio post-close.

Broad incumbents

• Novo Nordisk: Global leader in GLP-1 therapies (Ozempic, Wegovy) and the reference brand holder whose products EMS now competes against in Brazil via Ozivy, Olire, and Lirux. Novo Nordisk sets the price benchmark EMS undercuts by ~36%.
• Eli Lilly: Global GLP-1 innovator (Mounjaro, Zepbound) entering Brazil's R$5.7B GLP-1 market. As a global incumbent with deeper clinical data, Lilly represents the primary competitive threat to EMS's domestic peptide platform.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, providing a comparable operating model for high-volume, low-margin generics production at global scale. Useful benchmark for EMS's generics manufacturing economics.
• Sanofi: French multinational that sold both Medley (R$3.2B) and Dermacyd (€66M) to EMS. Sanofi operates in Brazil's prescription, generics, and consumer health segments, providing a relevant incumbent reference for portfolio diversification strategy.

Emerging players

• Idorsia Pharmaceuticals: Swiss specialty pharma that partnered with EMS in January 2026 for Latin America distribution of QUVIVIQ (insomnia drug). Idorsia is an emerging player using EMS as a regional commercialization channel, making them a thematic partner/peer in specialty pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/EMSfarmaceutica
• LinkedInlinkedin.com/company/ems
• Instagraminstagram.com/emsfarmaceutica
• Xx.com/emsfarmaceutica

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMS